2009
DOI: 10.1016/j.vaccine.2009.07.102
|View full text |Cite
|
Sign up to set email alerts
|

Immunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine: A phase III study in a large population of Asian adults

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

12
67
1

Year Published

2010
2010
2022
2022

Publication Types

Select...
4
2
1

Relationship

1
6

Authors

Journals

citations
Cited by 89 publications
(80 citation statements)
references
References 12 publications
12
67
1
Order By: Relevance
“…Similarly, the immunogenicity of both seasonal influenza vaccines 16 and other non-adjuvanted H1N1 vaccines 22 in young children is less than in older children and adults. New-generation adjuvants (such as MF59 and AS03 B ) have been used to improve immunogenicity 13,14,35 and in this study the split-virion adjuvanted vaccine was highly immunogenic, even in young children, but was slightly less immunogenic in older children than in infants (3% per year with age), a pattern not previously described for inactivated vaccines.…”
Section: Chaptersupporting
confidence: 56%
See 2 more Smart Citations
“…Similarly, the immunogenicity of both seasonal influenza vaccines 16 and other non-adjuvanted H1N1 vaccines 22 in young children is less than in older children and adults. New-generation adjuvants (such as MF59 and AS03 B ) have been used to improve immunogenicity 13,14,35 and in this study the split-virion adjuvanted vaccine was highly immunogenic, even in young children, but was slightly less immunogenic in older children than in infants (3% per year with age), a pattern not previously described for inactivated vaccines.…”
Section: Chaptersupporting
confidence: 56%
“…Increased reactogenicity was seen with an MF59-adjuvanted H1N1 vaccine in children, 37 as well as in adult trials of oil-in-water adjuvanted vaccines. [13][14][15]23,35 The AS03 B -adjuvanted vaccine in this trial was similarly associated with more local reactions, and some increase in systemic reactions, compared with the whole-virion vaccine. The higher reactogenicity observed with the split-virion adjuvanted vaccine may influence parental uptake of the vaccine.…”
mentioning
confidence: 76%
See 1 more Smart Citation
“…AS03 has been used in the product Prepandrix (H5N1 vaccine from GSK) in EU for a few years. This adjuvant has been shown to enhance the initial priming effect of pandemic influenza vaccination and promote a rapid humoral response to a single boosting dose with a heterologous strain, not only reducing the dose of the antigen (up to 24 times) but also offering a better cross-protection against drifted strains in young, elderly, or Asian subjects [149,150]. In different studies, administration of AS03-adjuvanted H1N1 pandemic vaccine generated same level of immunogenicity as unadjuvanted vaccine at a four-fold higher dose in adults [151], and long-term protection in health care workers [152].…”
Section: Emulsionsmentioning
confidence: 99%
“…CEL-1000 (18-mer) is an analogue of peptide G (a peptide from human MHCII beta chain, aa [135][136][137][138][139][140][141][142][143][144][145][146][147][148][149], which is known to enhance immune responses of other immunogenic peptides. They can be conjugated to HIV (HGP-30) and malaria peptides as potential vaccines.…”
Section: Specific Peptides/proteinsmentioning
confidence: 99%